---
title: "AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295708152.md"
description: "Secured a $15.3 million funding through milestone warrants, which may also generate up to $34.0 million in total gross proceeds. This financial boost will aid in the ongoing progress of the ABP-450 development program."
datetime: "2026-08-12T20:29:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295708152.md)
  - [en](https://longbridge.com/en/news/295708152.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295708152.md)
generator: "portal-rs"
---

# AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Secured a $15.3 million funding through milestone warrants, which may also generate up to $34.0 million in total gross proceeds. This financial boost will aid in the ongoing progress of the ABP-450 development program.

### Related Stocks

- [AEON.US](https://longbridge.com/en/quote/AEON.US.md)

## Related News & Research

- [AEON Biopharma’s Timothy P. Lynch files initial beneficial ownership statement](https://longbridge.com/en/news/296658780.md)
- [AEON Biopharma Q2 net loss narrows on warrant gain; cash runway extended](https://longbridge.com/en/news/295705604.md)
- [Nexera Technologies Resets Warrant Exercise Price to $1.6148 Effective September 3, 2026](https://longbridge.com/en/news/297973575.md)
- [REG - Sareum Holdings PLC - Exercise of Warrants](https://longbridge.com/en/news/297811946.md)
- [CLS issues 777,624 warrants in directed placement at SEK 1.9 exercise price](https://longbridge.com/en/news/297947522.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**